UY27727A1 - Nueva composicion farmacéutica- - Google Patents

Nueva composicion farmacéutica-

Info

Publication number
UY27727A1
UY27727A1 UY27727A UY27727A UY27727A1 UY 27727 A1 UY27727 A1 UY 27727A1 UY 27727 A UY27727 A UY 27727A UY 27727 A UY27727 A UY 27727A UY 27727 A1 UY27727 A1 UY 27727A1
Authority
UY
Uruguay
Prior art keywords
pharmaceutical composition
particles
new pharmaceutical
compound
administration
Prior art date
Application number
UY27727A
Other languages
English (en)
Inventor
Berg Mats
Holmberg Christina
Lundberg Per Johan
Anders Ringberg
Sven Morein
Original Assignee
Astrazeneca Ab Y Astrazeca Uk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Y Astrazeca Uk filed Critical Astrazeneca Ab Y Astrazeca Uk
Publication of UY27727A1 publication Critical patent/UY27727A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glanulating (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se relaciona con partículas porosas que comprenden uno o más compuestos antiinflamatorios no esteroideos dadores de NO y con nueva composición sólida para la administración de un compuesto que comprende dichas partículas opcionalmente en combinación con un segundo compuesto activo. Más aún, la invención se relaciona con procesos para producir dichas partículas porosas y composición sólida para la administración de un compuesto así como el uso de dichas partículas y composición en la fabricación de un medicamento.
UY27727A 2002-03-22 2003-03-20 Nueva composicion farmacéutica- UY27727A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200895A SE0200895D0 (sv) 2002-03-22 2002-03-22 New pharmaceutical composition

Publications (1)

Publication Number Publication Date
UY27727A1 true UY27727A1 (es) 2003-10-31

Family

ID=20287374

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27727A UY27727A1 (es) 2002-03-22 2003-03-20 Nueva composicion farmacéutica-

Country Status (9)

Country Link
US (1) US20050129774A1 (es)
EP (1) EP1490033A1 (es)
JP (2) JP2005533751A (es)
AR (1) AR038951A1 (es)
AU (1) AU2003216006A1 (es)
SE (1) SE0200895D0 (es)
TW (1) TW200307564A (es)
UY (1) UY27727A1 (es)
WO (1) WO2003080029A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
IT1319202B1 (it) 2000-10-12 2003-09-26 Nicox Sa Farmaci per le malattie a base infiammatoria.
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
JP4708795B2 (ja) 2002-12-20 2011-06-22 ニコノヴァム エービー 物理的および化学的に安定なニコチン−含有粒状物質
SE0301880D0 (sv) * 2003-06-25 2003-06-25 Astrazeneca Uk Ltd New drug delivery composition
JP2007511518A (ja) * 2003-11-13 2007-05-10 アルザ・コーポレーシヨン 溶融ブレンド分散体
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
WO2009012425A2 (en) * 2007-07-19 2009-01-22 Logigal Therapeutics, Inc. Compositions including leukotriene antagonists and nsaids and methods of using the same
WO2009149053A2 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Naproxcinod process and solid dispersion
WO2010031552A1 (en) * 2008-09-17 2010-03-25 Niconovum Ab Process for preparing snuff composition
DE102010052847A1 (de) * 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
AU2014322985B2 (en) * 2013-09-20 2019-05-16 Tillotts Pharma Ag Delayed release pharmaceutical formulation
JP6557935B2 (ja) 2014-11-18 2019-08-14 国立研究開発法人物質・材料研究機構 多孔性粒子の製造方法
GB201502073D0 (en) 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd HDEG technology
GB201502077D0 (en) * 2015-02-09 2015-03-25 Cubic Pharmaceuticals Ltd And Delta Pharmaceuticals Ltd Improved hme technology
WO2023212063A1 (en) * 2022-04-29 2023-11-02 Freeman John J Method and composition for treating lung diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2700141B2 (ja) * 1993-09-17 1998-01-19 富士化学工業株式会社 リン酸水素カルシウム及びその製法並びにそれを用いた賦形剤
JPH08301763A (ja) * 1995-04-28 1996-11-19 Dainippon Pharmaceut Co Ltd 易溶性粉末状医薬組成物およびその製造方法
JP2002533380A (ja) * 1998-12-23 2002-10-08 アルザ・コーポレーション 多孔性粒子を含む剤形
EP1183010A2 (en) * 1999-06-04 2002-03-06 ALZA Corporation Implantable gel compositions and method of manufacture
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
JP2001316248A (ja) * 2000-02-28 2001-11-13 Eisai Co Ltd 油状薬物含有組成物の製造方法
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
ITMI20021392A1 (it) * 2002-06-25 2003-12-29 Nicox Sa Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Also Published As

Publication number Publication date
SE0200895D0 (sv) 2002-03-22
TW200307564A (en) 2003-12-16
EP1490033A1 (en) 2004-12-29
US20050129774A1 (en) 2005-06-16
JP2010285445A (ja) 2010-12-24
AR038951A1 (es) 2005-02-02
AU2003216006A1 (en) 2003-10-08
JP2005533751A (ja) 2005-11-10
WO2003080029A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
UY27727A1 (es) Nueva composicion farmacéutica-
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
CL2008001951A1 (es) Compuestos derivados de imidazo[1,2-a]pirimidin-2-ilmetil sustituidos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el trastorno del sueno, depresion, ansiedad, trastorno relacionado con el abuso de sustancias, entre otras.
GT199900203A (es) Composiciones de celecoxib.
CL2010001348A1 (es) Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad.
ATE509634T1 (de) Pharmazeutische formulierungen mit incretin- peptid und aprotisch-polarem lösungsmittel
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
TR201906970T4 (tr) Fenilefrin ihtiva eden sıvı formülasyonlar.
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
UY27720A1 (es) Aroilpiridinonas monocíclicas,
UY30759A1 (es) Compuestos quimicos
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
SV2006002218A (es) Fenilaminotiazoles sustituidos y su uso ref.bhc041280-sv
MXPA06011467A (es) Combinacion de sustancias activas que comprenden un carbinol combinado con al menos un farmaco antiinflamatorio no esteroideo (nsaid).
CY1112625T1 (el) Παρατεταμενης διαρκειας τοπικη αναισθητικη συνθεση η οποια περιεχει sαιβ
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
DE60312523D1 (de) Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
ECSP088763A (es) Nuevas combinaciones terapéuticas para el tratamiento de la depresión
AR057148A1 (es) Combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
CL2008003576A1 (es) Compuestos derivados de amida del acido 6,7-dihidro-5h-imidazo[1,2-alfa]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y usos en el tratamiento de una afeccion inflamatoria.
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
CL2009001089A1 (es) Compuestos derivados de indolo[2,1-a][2]benzacepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126